Literature DB >> 34432157

Pharmacophore modeling and 3D-QSAR study for the design of novel α-synuclein aggregation inhibitors.

Jixia Yang1, Jiajing Hu2, Gongzheng Zhang1, Li Qin2, Hongliang Wen3, Yun Tang4.   

Abstract

Alpha-synuclein (α-syn), as a highly soluble presynaptic protein expressed in the brain, plays an important role in recycling synaptic vesicles and regulating the synthesis, storage, and release of neurotransmitters. Accumulation of α-syn in Lewy bodies and Lewy neurites is the pathological hallmark of Parkinson's disease (PD), so inhibition of α-syn aggregation may provide a novel approach for treating PD. In this study, the 3D structure of α-syn was downloaded from Protein Data Bank (PDB ID: 2N0A). A ligand-based pharmacophore model was conducted on a set of 43 diverse α-syn ligands, and the results suggested that two hydrogen-bond acceptors, one hydrophobic group, and two aromatic rings were significant to the inhibition of α-syn aggregation. A ligand-based 3D-QSAR model was also established with good statistical significance (R2 = 0.920) and excellent predictive ability (Q2 = 0.752). Novel indolinone derivatives were designed and synthesized based on the pharmacophore model. Subsequently, the 3D-QSAR model was used to predict the inhibitory activities towards α-syn aggregation, and the actual inhibitory activities were evaluated by thioflavin-T assay in vitro with the best inhibitory activity reaching 45.08%. The fitting results indicated that the built pharmacophore and 3D-QSAR models provided better reliability and accuracy for compound modification and prediction of the activity thereof. A ligand-based pharmacophore modeling and 3D-QSAR study have been performed on a set of 43 diverse ligands for α-synuclein for the first time. Based on the best pharmacophore modeling, novel indolinone derivatives were designed and synthesized, and the inhibitory activities for α-synuclein aggregation were evaluated by thioflavin-T assay in vitro, which preliminary indicated that five pharmacophore sites (two hydrogen bond acceptors (A), a hydrophobic group (H), and two aromatic rings (R)) in compounds contribute to the inhibitory activities. In the study, the built pharmacophore modeling and 3D-QSAR provided better reliability and accuracy for compound modification and prediction of the activity thereof.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  3D-QSAR; Alpha-synuclein; Indolinone; Parkinson’s disease; Pharmacophore

Mesh:

Substances:

Year:  2021        PMID: 34432157     DOI: 10.1007/s00894-021-04881-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  20 in total

1.  Design, Synthesis, and Characterization of 3-(Benzylidene)indolin-2-one Derivatives as Ligands for α-Synuclein Fibrils.

Authors:  Wenhua Chu; Dong Zhou; Vrinda Gaba; Jialu Liu; Shihong Li; Xin Peng; Jinbin Xu; Dhruva Dhavale; Devika P Bagchi; André d'Avignon; Naomi B Shakerdge; Brian J Bacskai; Zhude Tu; Paul T Kotzbauer; Robert H Mach
Journal:  J Med Chem       Date:  2015-07-31       Impact factor: 7.446

2.  Small molecule inhibitors of alpha-synuclein filament assembly.

Authors:  Masami Masuda; Nobuyuki Suzuki; Sayuri Taniguchi; Takayuki Oikawa; Takashi Nonaka; Takeshi Iwatsubo; Shin-ichi Hisanaga; Michel Goedert; Masato Hasegawa
Journal:  Biochemistry       Date:  2006-05-16       Impact factor: 3.162

3.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal.

Authors:  L Maroteaux; J T Campanelli; R H Scheller
Journal:  J Neurosci       Date:  1988-08       Impact factor: 6.167

Review 4.  A refined concept: α-synuclein dysregulation disease.

Authors:  Hideki Mochizuki; Chi-Jing Choong; Eliezer Masliah
Journal:  Neurochem Int       Date:  2018-01-02       Impact factor: 3.921

5.  α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells.

Authors:  Christian Hansen; Elodie Angot; Ann-Louise Bergström; Jennifer A Steiner; Laura Pieri; Gesine Paul; Tiago F Outeiro; Ronald Melki; Pekka Kallunki; Karina Fog; Jia-Yi Li; Patrik Brundin
Journal:  J Clin Invest       Date:  2011-01-18       Impact factor: 14.808

Review 6.  Current approaches to the treatment of Parkinson's Disease.

Authors:  J Michael Ellis; Matthew J Fell
Journal:  Bioorg Med Chem Lett       Date:  2017-07-29       Impact factor: 2.823

Review 7.  The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.

Authors:  D F Clayton; J M George
Journal:  Trends Neurosci       Date:  1998-06       Impact factor: 13.837

8.  The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years.

Authors:  Mariese A Hely; Wayne G J Reid; Michael A Adena; Glenda M Halliday; John G L Morris
Journal:  Mov Disord       Date:  2008-04-30       Impact factor: 10.338

9.  Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo.

Authors:  Elodie Angot; Jennifer A Steiner; Carla M Lema Tomé; Peter Ekström; Bengt Mattsson; Anders Björklund; Patrik Brundin
Journal:  PLoS One       Date:  2012-06-21       Impact factor: 3.240

Review 10.  Advances in the development of imaging probes and aggregation inhibitors for alpha-synuclein.

Authors:  Ming-Ming Xu; Philip Ryan; Santosh Rudrawar; Ronald J Quinn; Hai-Yan Zhang; George D Mellick
Journal:  Acta Pharmacol Sin       Date:  2019-10-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.